- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03391388
3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer
A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the rate of adverse cosmesis (defined as fair or poor cosmesis) with accelerated 3 fraction APBI at 3 years, compared to baseline.
SECONDARY OBJECTIVES:
I. To evaluate the acute and late toxicities of accelerated 3 fraction APBI. II. To evaluate local disease control of accelerated 3 fraction APBI. III. To assess the rate of patient reported adverse cosmesis at 2 years, compared to baseline.
IV. To assess quality of life and other patient reported outcomes following accelerated 3 fraction APBI.
V. To compare the local control, acute and late toxicities, cosmesis, quality of life and other patient reported outcomes between the three radiation therapy techniques (3D-CRT, proton, brachytherapy).
VI. To evaluate clinical features, dose-volume parameters, and genetic variants associated with fair and poor cosmetic outcome.
OUTLINE: Patients are assigned to 1 of 3 cohorts.
COHORT I: Patients undergo 3D-CRT APBI for 3-5 days.
COHORT II: Patients undergo proton beam radiation therapy APBI for 3-5 days.
COHORT III: Patients undergo brachytherapy ABPI for 3-5 days.
After completion of study treatment, patients are followed up at 12 weeks, 12 months, and annually for 5 years.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic Hospital
-
-
Florida
-
Jacksonville, Florida, United States, 32224-9980
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Grade 1-3 invasive ductal, mammary, mucinous, tubular, colloidal, or pure ductal carcinoma in situ (DCIS) measuring =< 2.5 cm on final pathology (the tumor should be clinical stage T1N0M0 in patients electing brachytherapy in whom the catheter will be placed intraoperatively)
- Estrogen receptor (ER)+ (ER- DCIS meeting other eligibility criteria are eligible)
- Unicentric: patients with microscopic multifocality are eligible as long as the total pathologic tumor size is =< 2.5 cm
- Surgical treatment of the breast must have been lumpectomy
- The final margins of the resected specimen must be histologically free of tumor
- Patients with DCIS do not require an axillary staging procedure; for patients with invasive breast cancer (except T1mi), an axillary staging procedure should be performed (either sentinel lymph node biopsy alone or axillary dissection and the axillary node must be pathologically negative) and they should be pathologically node negative; Note: Patients with N0 (i+) tumors on sentinel lymph node mapping or dissection (i.e., if the tumor deposit is 0.2 mm or less as determined by immunohistochemistry or hematoxylin and eosin staining) will also be eligible
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Ability to complete questionnaire(s) by themselves or with assistance
- Ability to elect radiotherapy care in conjunction with their physician
- Able and willing to provide written informed consent
- Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- Willing to provide tissue and blood samples for correlative research purposes
- Rochester and Arizona patients: Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study and collect involved blood specimen prior to the start of radiation therapy, IRB number 15-000136.
Exclusion Criteria:
Any of the following because this study involves therapy that has known genotoxic, mutagenic and teratogenic effects:
- Pregnant women
- Nursing women
- Women of childbearing potential who are unwilling to employ adequate contraception
- Neoadjuvant chemotherapy
- Prior history of ipsilateral breast cancer
- Prior radiation therapy to the ipsilateral breast or thorax
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Active collagen-vascular disease that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- Paget?s disease of the breast
- Proven multicentric carcinoma (DCIS or invasive) in more than one quadrant or separated by 4 or more centimeters or diffuse (> 1 quadrant) suspicious calcifications
- Histologic evidence of angiolymphatic invasion (ALI); Note: Cases termed focally suspicious for ALI but where no definitive ALI is found are eligible
- Surgical margins that cannot be microscopically assessed or that are positive
- Pathologic tumor > 2.5 cm in size
- Metastatic disease
- Patients for whom the delivery of APBI is not feasible or any of the dosimetric treatment criteria have not been met
- BRCA 1/2 mutation; Note: Patients are not required to undergo BRCA1 and BRCA2 or other genetic mutation tests in order to enroll on the study. However, in the event a patient is tested and is found to be a mutation carrier, she would be excluded from the study
- Breast implants (patients who have had implants removed are eligible)
- Extensive intraductal component
- Active connective tissue disease
- Reduction mammoplasty if 3DCRT or proton APBI are planned
- Last surgery > 10 weeks from enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort I (3D-CRT APBI)
Patients undergo 3D-CRT APBI for 3-5 days.
|
Correlative studies
Ancillary studies
Other Names:
Undergo 3D-CRT, catheter-based brachytherapy, or proton APBI
Other Names:
Undergo 3D-CRT APBI
|
Experimental: Cohort II (proton APBI)
Patients undergo proton beam radiation therapy APBI for 3-5 days.
|
Correlative studies
Ancillary studies
Other Names:
Undergo 3D-CRT, catheter-based brachytherapy, or proton APBI
Other Names:
Undergo proton APBI
|
Experimental: Cohort III (brachytherapy APBI)
Patients undergo brachytherapy ABPI for 3-5 days.
|
Correlative studies
Ancillary studies
Other Names:
Undergo 3D-CRT, catheter-based brachytherapy, or proton APBI
Other Names:
Undergo catheter-based brachytherapy APBI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage difference in patients with adverse cosmesis (fair or poor cosmesis)
Time Frame: At 3 years
|
The percentage difference in patients with adverse cosmesis will be estimated using a binomial estimator (number of women who had an adverse cosmesis event at 3 years minus number of women who had an adverse cosmesis event at baseline, and then divided by total number of women in the primary analysis) and a 95% exact binomial confidence interval.
|
At 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distant recurrence
Time Frame: Up to 5 years
|
The distant breast cancer recurrence cumulative incidence will be estimated using a competing risks method (Gooley et al.).
The competing risks will be local/regional breast cancer recurrence and death.
|
Up to 5 years
|
Incidence of acute adverse events (AEs)
Time Frame: Up to 90 days post-radiation therapy (RT)
|
The maximum grade for each type of acute AE will be recorded for each patient.
Data will be summarized as frequencies and relative frequencies.
|
Up to 90 days post-radiation therapy (RT)
|
Incidence of late adverse events
Time Frame: Up to 3 years post-RT
|
The maximum grade for each type of acute AE will be recorded for each patient.
Data will be summarized as frequencies and relative frequencies.
|
Up to 3 years post-RT
|
Invasive disease free survival
Time Frame: From study registration until the occurrence of one of the events in a composite endpoint, assessed up to 5 years
|
This endpoint includes invasive IBTR, regional invasive breast cancer recurrence, distant breast cancer recurrence, death due to any cause, contralateral invasive breast cancer, and second primary non-breast invasive disease.
The DFS will be estimated with a Kaplan-Meier estimator and curve.
Estimates will be given for specific time points along with 95% confidence interval (CI)s.
|
From study registration until the occurrence of one of the events in a composite endpoint, assessed up to 5 years
|
Ipsilateral breast tumor recurrence (IBTR)
Time Frame: At 3 years
|
IBTR is defined as both invasive and non-invasive breast cancer involving the same breast parenchyma as the original tumor.
Will be estimated using a competing risks method (Gooley et al.).
The competing risks will be regional/distant breast cancer recurrence and death.
|
At 3 years
|
Overall survival
Time Frame: From registration to death due to any cause, assessed up to 5 years
|
This endpoint includes invasive IBTR, regional invasive breast cancer recurrence, distant breast cancer recurrence, death due to any cause, contralateral invasive breast cancer, and second primary non-breast invasive disease.
Will be estimated with a Kaplan-Meier estimator and curve.
Estimates will be given for specific time points along with 95% CIs.
|
From registration to death due to any cause, assessed up to 5 years
|
Panel-assessed cosmetic outcome
Time Frame: Up to 5 years
|
Will be assessed by a panel of breast cancer medical providers using digital photographs.
The values of the cosmesis instruments (patient self-reported and panel-assessed) will be summarized with the frequencies of fair or poor cosmesis events at baseline and 3 years, and the difference at 3 years, as well as their relative exact binomial confidence intervals.
|
Up to 5 years
|
Patient self-reported cosmetic outcomes assessed using a modified Harvard Cosmesis Scale in the Breast Cancer Treatment Outcome Scale (BCTOS)
Time Frame: At 3 years
|
The values of the cosmesis instruments (patient self-reported and panel-assessed) will be summarized with the frequencies of fair or poor cosmesis events at baseline and 3 years, and the difference at 3 years, as well as their relative exact binomial confidence intervals.
|
At 3 years
|
Quality of life (QOL) assessed by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Time Frame: Up to 5 years
|
The QOL measurements will be summarized at each time point as mean +/- standard deviation (SD) and median (minimum value, maximum value).
Changes in the QOL measurements from baseline will be determined at each follow-up measurement.
These will be displayed as spaghetti plots.
The assessment of the changes at each time point will be done with a paired t-test or Wilcoxon signed rank test, whichever is appropriate.
|
Up to 5 years
|
Regional recurrence
Time Frame: Up to 5 years
|
The regional breast cancer recurrence cumulative incidence will be estimated using a competing risks method (Gooley et al.).
The competing risks will be local/distant breast cancer recurrence and death.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Mutter, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma, Ductal
- Carcinoma in Situ
- Breast Neoplasms
- Carcinoma
- Breast Carcinoma In Situ
- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Lobular
- Carcinoma, Ductal, Breast
Other Study ID Numbers
- MC1532 (Other Identifier: Mayo Clinic)
- NCI-2017-02363 (Other Identifier: CTRP (Clinical Trials Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Estrogen Receptor Positive
-
National Cancer Institute (NCI)TerminatedStage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor PositiveUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...TerminatedEstrogen Receptor Positive Breast Cancer | Androgen Receptor Gene Overexpression | Progesterone Receptor Positive Tumor | Metastatic Breastcancer | Estrogen Receptor Negative Neoplasm | Progesterone Receptor Negative NeoplasmItaly
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaboratorsTerminatedStage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Merck Sharp & Dohme LLCCompletedStage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast CarcinomaUnited States
-
Eisai Inc.CompletedBreast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast CancerFrance, United Kingdom, United States
-
Syndax PharmaceuticalsCompletedBreast Cancer | ER+ Breast Cancer | Estrogen Receptor-Positive Breast Cancer | Breast Cancer, Estrogen Receptor-PositiveUnited States, Czechia, Canada, Hungary, Russian Federation
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7United States, Puerto Rico
-
AC Camargo Cancer CenterH. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingNeuroendocrine Tumors | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive TumorUnited States, Brazil
-
National Cancer Institute (NCI)TerminatedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditionsUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States